ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its partner for Japan, Torii Pharmaceutical Co., Ltd. (TSE: 4551), has reported positive results from its Phase II/III trial into ALK’s sublingual allergy immunotherapy tablet (SLIT-tablet) for house dust mite-induced allergic rhinitis (hay fever).
Help employers find you! Check out all the jobs and post your resume.
